/PRNewswire/ CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted.
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) has been assigned an average rating of “Moderate Buy” from the eight ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among […]
/PRNewswire/ CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted.
/PRNewswire/ CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted.
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 15,970,000 shares, an increase of 18.3% from the February 28th total of 13,500,000 shares. Based on an average daily volume of 2,950,000 shares, the short-interest ratio is […]